Roche asks EU to approve Avastin for advanced breast cancer
Roche Holding AG, the world's biggest maker of cancer drugs, asked European Union regulators to approve its Avastin medicine for use as a primary treatment of advanced breast cancer. The filing is based on a study that shows combining Avastin with chemotherapy doubled the time women live without their breast cancer progressing, the Basel, Switzerland-based company said in an e-mailed statement today. Breast cancer is the leading cause of cancer death worldwide in women. Roche aims to expand sales of Avastin, its fastest-growing drug, with new research that shows the medicine works when used earlier and also in different types of cancer. Some analysts predict annual sales of the drug may climb to between $5 billion and $10 billion if it wins approval for new uses. Avastin is the first treatment that inhibits angiogenesis – the growth of a network of blood vessels that supply nutrients and oxygen to cancerous tissues. Avastin targets a naturally occurring protein called VEGF (Vascular Endothelial Growth Factor), a key mediator of angiogenesis, thus choking off the blood supply that is essential for the growth of the tumour and its spread throughout the body (metastasis). Avastin was approved in February 2004 in the US and has received full approval in EU and Switzerland in January 2005. (Roche, Bloomberg)
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.